BPMC - Deciphera Pharmaceuticals: Resolving The Limitation Of Tyrosine Kinase Inhibitors
Deciphera Pharmaceuticals (DCPH) is a small company with a pipeline of small molecules targeting various causes of cancer. Lead candidate Ripretinib is an orally administered kinase switch control inhibitor being developed for the treatment of "gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis ((ASM)), gliomas, and other solid tumors driven by tyrosine-protein kinase KIT (KIT) or platelet-derived growth factor alpha (PDGFR?) kinase (where genetic mutations or alterations in these kinases play a crucial role in the biology of these tumors leading to drug-resistance and disease progression)."
Kinase inhibition has been a very successful biology